Literature DB >> 10515819

Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock.

S M Opal1, P J Scannon, J L Vincent, M White, S F Carroll, J E Palardy, N A Parejo, J P Pribble, J H Lemke.   

Abstract

Plasma endotoxin and lipopolysaccharide-binding protein (LBP) levels were measured in a group of 253 patients at the onset of severe sepsis and/or septic shock. Endotoxin levels were significantly greater than control levels (n=33; mean +/- SD, 5.1+/-7.3 pg/mL) in 78.3% of patients. Median endotoxin levels in patients with sepsis were 300 pg/mL (25%-75% interquartile range, 110-726 pg/mL). LBP levels were elevated in 97% of patients compared with normal control values of 4.1+/-1.65 microgram/mL. Median LBP levels in patients with sepsis were 31.2 microgram/mL (interquartile range, 22.5-47.7 microgram/mL). Median endotoxin levels at study entry were more highly elevated (515 vs. 230 pg/mL; P<.01), and LBP levels were less highly elevated (28.0 vs. 33.2 microgram/mL; P<.05) in nonsurvivors than survivors over the 28-day study period. No correlation was found between endotoxin and LBP levels. The quantitative level of both endotoxin and LBP may have prognostic significance in patients with severe sepsis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10515819     DOI: 10.1086/315093

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  169 in total

Review 1.  A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein.

Authors:  O Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 2.  [Endotoxins. Pathogenetic meaning of sepsis].

Authors:  H Rensing
Journal:  Anaesthesist       Date:  2003-12       Impact factor: 1.041

Review 3.  Risk factors for sepsis after percutaneous renal stone surgery.

Authors:  Evgeniy I Kreydin; Brian H Eisner
Journal:  Nat Rev Urol       Date:  2013-09-03       Impact factor: 14.432

4.  Lipopolysaccharide binding protein is down-regulated during acute liver failure.

Authors:  Grace L Su; Robert J Fontana; Kartik Jinjuvadia; Jill Bayliss; Stewart C Wang
Journal:  Dig Dis Sci       Date:  2012-01-26       Impact factor: 3.199

5.  Acute-phase concentrations of lipopolysaccharide (LPS)-binding protein inhibit innate immune cell activation by different LPS chemotypes via different mechanisms.

Authors:  Lutz Hamann; Christian Alexander; Cordula Stamme; Ulrich Zähringer; Ralf R Schumann
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

6.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

7.  Geniposide plays an anti-inflammatory role via regulating TLR4 and downstream signaling pathways in lipopolysaccharide-induced mastitis in mice.

Authors:  Xiaojing Song; Wen Zhang; Tiancheng Wang; Haichao Jiang; Zecai Zhang; Yunhe Fu; Zhengtao Yang; Yongguo Cao; Naisheng Zhang
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

Review 8.  Immunopathophysiology of trauma-related acute kidney injury.

Authors:  David A C Messerer; Rebecca Halbgebauer; Bo Nilsson; Hermann Pavenstädt; Peter Radermacher; Markus Huber-Lang
Journal:  Nat Rev Nephrol       Date:  2020-09-21       Impact factor: 28.314

9.  Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection.

Authors:  Ronald W Clark; David Cunningham; Yang Cong; Timothy A Subashi; George T Tkalcevic; David B Lloyd; James G Boyd; Boris A Chrunyk; George A Karam; Xiayang Qiu; Ing-Kae Wang; Omar L Francone
Journal:  J Lipid Res       Date:  2009-10-21       Impact factor: 5.922

10.  Ablation of Akt2 protects against lipopolysaccharide-induced cardiac dysfunction: role of Akt ubiquitination E3 ligase TRAF6.

Authors:  Yingmei Zhang; Xihui Xu; Asli F Ceylan-Isik; Maolong Dong; Zhaohui Pei; Yan Li; Jun Ren
Journal:  J Mol Cell Cardiol       Date:  2014-05-05       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.